WellnessPhase 2/3NCT06640465
Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations
A Phase 2/3 study testing Ubiquinol + geranylgeraniol, Geranylgeraniol and Ubiquinol in people with Wellness and Health, run by OvationLab at 6 sites in United States.
Trial summary
The primary purpose of this study is to compare the safety and effectiveness of commercially available dietary supplements believed to increase coenzyme Q10 (CoQ10) concentrations. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- What is being tested?
- Ubiquinol + geranylgeraniol, Geranylgeraniol and Ubiquinol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 6 sitesUnited States
- Study dates
- 12 Oct 2024to 17 Sep 2025
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult males or females age ≥ 40 years
- Ability to read and speak English
Who cannot join
- Daily use within the past 2 months of any dietary supplements containing CoQ10 or geranylgeraniol (GG)
- Taking a statin medication within the past 6 months
- Current daily usage of H2 blockers or PPI medications
- Current daily use of bisphosphonates
- Current daily tobacco smoker
- Known allergies to any substance in the study products
Show all 10Show fewer
- Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- Current diagnosis of a chronic health condition (e.g., cancer, Crohn's disease) deemed clinically contraindicated for the study protocol.
- Participant in a clinical trial in the previous 30 days.
- Participants unable to provide consent
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
Cornerstone Health Community
Centennial, Colorado, 80111
Functional Medicine of Idaho
Eagle, Idaho, 83616
True Health Center for Precision Medicine
El Dorado Hills, California, 95762
New Dawn Wellness and Medical Center
Houston, Texas, 77082
CTMD Research
Palm Springs, Florida, 33046
Vida Integrated Health
Seattle, Washington, 98122
About this study
Official title: A Randomized, Placebo-Controlled Trial Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations
The primary purpose of this study is to compare the safety and effectiveness of commercially available dietary supplements believed to increase coenzyme Q10 (CoQ10) concentrations.
An 8-week, randomized, placebo-controlled clinical trial will be conducted comparing the effectiveness of four commercially available dietary supplements on increasing CoQ10 concentrations and self-reported health outcomes.
- Being tested
- Ubiquinol + geranylgeraniol, Geranylgeraniol, Ubiquinol, Ubiquinone, Placebo
- Keywords
- Coenzyme Q10, CoQ10, Geranylgeraniol, GG, Ubiquinol, Ubiquinone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ubiquinol + geranylgeraniolDietary supplement
Combination of ubiquinol and geranylgeraniol
GeranylgeraniolDietary supplement
Geranylgeraniol alone
UbiquinolDietary supplement
Ubiquinol alone
UbiquinoneDietary supplement
Ubiquinone alone
PlaceboOther
Placebo capsule
| Study group | Role | What they receive |
|---|---|---|
| Ubiquinol + geranylgeraniol combination (Designs for Health - CoQnol™ 200) | Experimental | Not described Receives: Dietary Supplement: Ubiquinol + geranylgeraniol |
| Geranylgeraniol (Annatto-GG™ 300) | Experimental | Not described Receives: Dietary Supplement: Geranylgeraniol |
| Ubiquinol (Jarrow Formulas QH-absorb® 200 mg) | Experimental | Not described Receives: Dietary Supplement: Ubiquinol |
| Ubiquinone (NOW CoQ10 200mg) | Experimental | Not described Receives: Dietary Supplement: Ubiquinone |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma Coenzyme Q10
Measured: Baseline and 8 weeks
Secondary outcomes (5)
Comprehensive metabolic panel
Alanine aminotransferase (ALT) in units per liter (U/L)
Measured: Baseline and 8 weeks
Lipid panel
Low-density lipoprotein (LDL) in milligrams per deciliter (mg/dL)
Measured: Baseline and 8 weeks
Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health
Raw scores range from 4 to 20, with higher scores indicating better global physical or mental health compared to the average
Measured: Baseline and 8 weeks
Profile of Mood States - Vigor Subscale
Scores range from 0 to 32, with higher scores indicating better energy levels
Measured: Baseline and 8 weeks
Short Form 36 (SF-36) - Vitality Subscale
Scores range from 0 to 100, with higher scores indicating greater vitality
Measured: Baseline and 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start12 Oct 2024
- Primary completion17 Sep 2025
- Study completion17 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for WellnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- OvationLab
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06640465
- Sponsor's protocol ID
- OvationLab
- Status last verified
- Mar 2026
- First submitted
- 10 Oct 2024
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified participant data will be made available upon reasonable request.
Publications
D'Adamo CR, Leary M, Mote C, Ackerman R, Holthouse M, Binstock B, Adair E, Piedrahita G, Wehage S, Burke K. A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations. J Nutr Metab. 2026 Sep 27;2026:5589963. doi: 10.1155/jnme/5589963. eCollection 2026.
PubMed 42807157
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Placebo-Controlled Trial Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations
- ClinicalTrials.gov ID
- NCT06640465
- Acronym / sponsor ID
- OvationLab
- Keywords
- Coenzyme Q10, CoQ10, Geranylgeraniol, GG, Ubiquinol, Ubiquinone
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- OvationLabResearch network
- Study start
- 12 Oct 2024 (actual)
- Primary completion
- 17 Sep 2025 (actual)
- Study completion
- 17 Sep 2025 (actual)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to compare the safety and effectiveness of commercially available dietary supplements believed to increase coenzyme Q10 (CoQ10) concentrations.
An 8-week, randomized, placebo-controlled clinical trial will be conducted comparing the effectiveness of four commercially available dietary supplements on increasing CoQ10 concentrations and self-reported health outcomes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Ubiquinol + geranylgeraniol combination (Designs for Health - CoQnol™ 200) | Experimental | Dietary Supplement: Ubiquinol + geranylgeraniol |
| Geranylgeraniol (Annatto-GG™ 300) | Experimental | Dietary Supplement: Geranylgeraniol |
| Ubiquinol (Jarrow Formulas QH-absorb® 200 mg) | Experimental | Dietary Supplement: Ubiquinol |
| Ubiquinone (NOW CoQ10 200mg) | Experimental | Dietary Supplement: Ubiquinone |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adult males or females age ≥ 40 years
- Ability to read and speak English
Key exclusion criteria (10 listed)
- Daily use within the past 2 months of any dietary supplements containing CoQ10 or geranylgeraniol (GG)
- Taking a statin medication within the past 6 months
- Current daily usage of H2 blockers or PPI medications
- Current daily use of bisphosphonates
- Current daily tobacco smoker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ubiquinol + geranylgeraniolCombination of ubiquinol and geranylgeraniol | Dietary supplement | Ubiquinol + geranylgeraniol combination (Designs for Health - CoQnol™ 200) |
| GeranylgeraniolGeranylgeraniol alone | Dietary supplement | Geranylgeraniol (Annatto-GG™ 300) |
| UbiquinolUbiquinol alone | Dietary supplement | Ubiquinol (Jarrow Formulas QH-absorb® 200 mg) |
| UbiquinoneUbiquinone alone | Dietary supplement | Ubiquinone (NOW CoQ10 200mg) |
| PlaceboPlacebo capsule | Other | Placebo |
Primary outcome
Plasma Coenzyme Q10
Time frame: Baseline and 8 weeks
5 secondary outcomes
Comprehensive metabolic panel
Time frame: Baseline and 8 weeks
Lipid panel
Time frame: Baseline and 8 weeks
Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health
Time frame: Baseline and 8 weeks
Profile of Mood States - Vigor Subscale
Time frame: Baseline and 8 weeks
Short Form 36 (SF-36) - Vitality Subscale
Time frame: Baseline and 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
- Derived from this study: PubMed 42807157D'Adamo CR, Leary M, Mote C, Ackerman R, Holthouse M, Binstock B, Adair E, Piedrahita G, Wehage S, Burke K. A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations. J Nutr Metab. 2026 Sep 27;2026:5589963. doi: 10.1155/jnme/5589963. eCollection 2026.
- Individual participant dataSharing planned: Yes. Deidentified participant data will be made available upon reasonable request.
Related trials for Wellness
Not yet recruitingObservational study
Validation of the Healthcare Relationship Assessment Scale (ERA) in Health Sciences Students.
Health Adult Subjects, Communication
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Ubiquinol + geranylgeraniol, Geranylgeraniol and Ubiquinol in people with Wellness and Health, run by OvationLab at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma Coenzyme Q10 (time frame: Baseline and 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06640465, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.